Morphic (MORF) Stock Price, News & Analysis

Company Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $56.99 to $56.99
• 50-Day Range: $55.74 to $56.99
• 52-Week Range: $19.34 to $57.00
• Volume: 400 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $2.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.00
• Consensus Rating: Hold

Morphic Stock Analysis - MarketRank™

Morphic scored higher than 20% of companies evaluated by MarketBeat, and ranked 840th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Morphic has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Morphic has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Morphic has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MORF.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Morphic does not currently pay a dividend.

Dividend Growth

Morphic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.57

Short Interest

There is no current short interest data available for MORF.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Morphic insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.60% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MORF Stock Analysis - Frequently Asked Questions

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) posted its quarterly earnings results on Thursday, July, 25th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.96) by $0.19.

When did Morphic IPO?

Morphic (MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO.

What other stocks do shareholders of Morphic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), SPDR S&P 500 ETF Trust (SPY), Advanced Micro Devices (AMD), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/25/2024
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MORF
• CIK: 1679363
• Web: www.morphictx.com
• Phone: (781) 996-0955
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $57.00
• High Stock Price Target: $57.00
• Low Stock Price Target: $57.00
• Potential Upside/Downside: +0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$152.10 million
• Net Margins: N/A
• Pretax Margin: -29,119.96%
• Return on Equity: -26.62%
• Return on Assets: -25.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.13
• Quick Ratio: 24.13

Sales & Book Value

• Annual Sales: $520 thousand
• Price / Sales: 5,490.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.31 per share
• Price / Book: 4.63

Miscellaneous

• Outstanding Shares: 50,094,000
• Free Float: 37,270,000
• Market Cap: $2.85 billion
• Optionable: Optionable
• Beta: 1.49